## Bruno A Benitez

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3688180/publications.pdf

Version: 2024-02-01

62 papers 7,823 citations

32 h-index 55 g-index

74 all docs

74 docs citations

74 times ranked 10855 citing authors

#	Article	IF	CITATIONS
1	Proteinopathy and Longitudinal Cognitive Decline in Parkinson Disease. Neurology, 2022, 99, .	1.1	8
2	Exome sequencing revealed <i>PDE11A</i> as a novel candidate gene for early-onset Alzheimer's disease. Human Molecular Genetics, 2021, 30, 811-822.	2.9	12
3	Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. Neurobiology of Disease, 2021, 151, 105247.	4.4	3
4	Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy. Nature, 2021, 593, 255-260.	27.8	179
5	Genomic atlas of the proteome from brain, CSF and plasma prioritizes proteins implicated in neurological disorders. Nature Neuroscience, 2021, 24, 1302-1312.	14.8	105
6	Neuronal VCP loss of function recapitulates FTLD-TDP pathology. Cell Reports, 2021, 36, 109399.	6.4	25
7	Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms. Neuron, 2021, 109, 2413-2426.e7.	8.1	57
8	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq0 0 0 rgBT /Overlock	10 Jf 50 4	62 Td (edition 1,430
9	<i>DNAJC5</i> affects the endoâ€lysosomal pathway, APP processing, and AD pathology <i>in vitro</i> and <i>in vivo</i> . Alzheimer's and Dementia, 2021, 17, e054177.	0.8	O
10	Profiling the metabolic landscape of AD. Alzheimer's and Dementia, 2021, 17, e050086.	0.8	O
11	Functional exploration of AGFG2, a novel player in the pathology of Alzheimer disease Alzheimer's and Dementia, 2021, 17 Suppl 3, e054240.	0.8	1
12	Single nuclei RNA-sequencing of GWAS loci variant carriers elucidates cell-types and transcriptional profile alterations associated with Alzheimer disease Alzheimer's and Dementia, 2021, 17 Suppl 3, e054402.	0.8	0
13	Multi-omics approaches reveal a link between the MS4A gene loci, TREM2, and microglia function Alzheimer's and Dementia, 2021, 17 Suppl 3, e054553.	0.8	O
14	The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathologica, 2020, 139, 45-61.	7.7	51
15	Overlapping genetic architecture between Parkinson disease and melanoma. Acta Neuropathologica, 2020, 139, 347-364.	7.7	23
16	Functional genomic analyses uncover APOE-mediated regulationÂofÂbrain and cerebrospinal fluid beta-amyloid levels in Parkinson disease. Acta Neuropathologica Communications, 2020, 8, 196.	5.2	8
17	TREM2 activation on microglia promotes myelin debris clearance and remyelination in a model of multiple sclerosis. Acta Neuropathologica, 2020, 140, 513-534.	7.7	186
18	Macrophage secretion of miR-106b-5p causes renin-dependent hypertension. Nature Communications, 2020, 11, 4798.	12.8	36

#	Article	IF	CITATIONS
19	Examination of the Effect of Rare Variants in TREM2, ABI3, and PLCG2 in LOAD Through Multiple Phenotypes. Journal of Alzheimer's Disease, 2020, 77, 1469-1482.	2.6	18
20	Proteogenomic analysis of cerebrospinal fluid reveals causal role of proteins from the autophagyâ€lysosome pathway in Parkinson's disease. Alzheimer's and Dementia, 2020, 16, e043422.	0.8	0
21	<i>APOE</i> genotype regulates pathology and disease progression in synucleinopathy. Science Translational Medicine, 2020, 12, .	12.4	102
22	Cell-autonomous expression of the acid hydrolase galactocerebrosidase. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9032-9041.	7.1	8
23	A single-nuclei RNA sequencing study of Mendelian and sporadic AD in the human brain. Alzheimer's Research and Therapy, 2019, $11,71.$	6.2	131
24	The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Science Translational Medicine, 2019, 11, .	12.4	170
25	Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20097-20103.	7.1	68
26	Using global team science to identify genetic parkinson's disease worldwide. Annals of Neurology, 2019, 86, 153-157.	5.3	26
27	TREM2 brain transcript-specific studies in AD and TREM2 mutation carriers. Molecular Neurodegeneration, 2019, 14, 18.	10.8	58
28	Pleiotropic Effects of Variants in Dementia Genes in Parkinson Disease. Frontiers in Neuroscience, 2018, 12, 230.	2.8	21
29	Pooled-DNA target sequencing of Parkinson genes reveals novel phenotypic associations in Spanish population. Neurobiology of Aging, 2018, 70, 325.e1-325.e5.	3.1	6
30	Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?. Expert Opinion on Therapeutic Targets, 2018, 22, 587-598.	3.4	27
31	TMEM230 in Parkinson's disease. Neurobiology of Aging, 2017, 56, 212.e1-212.e3.	3.1	9
32	Primary fibroblasts from CSP $\hat{l}$ ± mutation carriers recapitulate hallmarks of the adult onset neuronal ceroid lipofuscinosis. Scientific Reports, 2017, 7, 6332.	3.3	20
33	Study of genetic variants in the BDNF, COMT, DAT1 and SERT genes in Colombian children with attention deficit disorder. Revista Colombiana De PsiquiatrÃa (English Ed ), 2017, 46, 222-228.	0.3	1
34	Parkinson disease polygenic risk score is associated with Parkinson disease status and age at onset but not with alpha-synuclein cerebrospinal fluid levels. BMC Neurology, 2017, 17, 198.	1.8	55
35	Resequencing analysis of five Mendelian genes andÂthe top genes from genome-wide association studies in Parkinson's Disease. Molecular Neurodegeneration, 2016, 11, 29.	10.8	70
36	Pooled-DNA Sequencing for Elucidating New Genomic Risk Factors, Rare Variants Underlying Alzheimer's Disease. Methods in Molecular Biology, 2016, 1303, 299-314.	0.9	3

#	Article	IF	Citations
37	Variants in GBA, SNCA, and MAPT influence Parkinson disease risk, age at onset, and progression. Neurobiology of Aging, 2016, 37, 209.e1-209.e7.	3.1	106
38	Clinically early-stage $CSP\hat{l}_{\pm}$ mutation carrier exhibits remarkable terminal stage neuronal pathology with minimal evidence of synaptic loss. Acta Neuropathologica Communications, 2015, 3, 73.	5.2	17
39	TREM2 is associated with increased risk for Alzheimer's disease in African Americans. Molecular Neurodegeneration, 2015, 10, 19.	10.8	130
40	Frontobasal gray matter loss is associated with the TREM2 p.R47H variant. Neurobiology of Aging, 2014, 35, 2681-2690.	3.1	39
41	Coding variants in TREM2 increase risk for Alzheimer's disease. Human Molecular Genetics, 2014, 23, 5838-5846.	2.9	263
42	<i>TREM2</i> Variant p.R47H as a Risk Factor for Sporadic Amyotrophic Lateral Sclerosis. JAMA Neurology, 2014, 71, 449.	9.0	221
43	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease. Nature, 2014, 505, 550-554.	27.8	425
44	Missense variant in TREML2 protects against Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1510.e19-1510.e26.	3.1	110
45	Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson's disease. Neurobiology of Aging, 2014, 35, 1958.e1-1958.e2.	3.1	19
46	O1-04-02: EXOME-SEQUENCING IN LATE-ONSET FAMILIES IDENTIFIED ADDITIONAL CANDIDATES GENES FOR ALZHEIMER'S DISEASE. , 2014, 10, P135-P135.		0
47	O1-04-05: NOVEL CODING VARIANTS IN TREM2 INCREASE RISK FOR ALZHEIMER'S DISEASE. , 2014, 10, P136-P1	36.	0
48	Genetic high throughput screening in Retinitis Pigmentosa based on high resolution melting (HRM) analysis. Experimental Eye Research, 2013, 116, 386-394.	2.6	14
49	TREM2 is associated with the risk of Alzheimer's disease in Spanish population. Neurobiology of Aging, 2013, 34, 1711.e15-1711.e17.	3.1	130
50	<i>TREM2</i> Variants in Alzheimer's Disease. New England Journal of Medicine, 2013, 368, 117-127.	27.0	2,385
51	Parkinson disease is not associated with C9ORF72 repeat expansions. Neurobiology of Aging, 2013, 34, 1519.e1-1519.e2.	3.1	44
52	GWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer's Disease. Neuron, 2013, 78, 256-268.	8.1	344
53	The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-ε4 Carriers. PLoS Genetics, 2013, 9, e1003685.	3.5	55
54	C9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease. JAMA Neurology, 2013, 70, 736.	9.0	92

#	Article	IF	CITATIONS
55	TREM2 and neurodegenerative disease. New England Journal of Medicine, 2013, 369, 1567-8.	27.0	81
56	Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort. Alzheimer's Research and Therapy, 2012, 4, 34.	6.2	103
57	Functional reduction of SK3-mediated currents precedes AMPA-receptor-mediated excitotoxicity in dopaminergic neurons. Neuropharmacology, 2011, 60, 1176-1186.	4.1	23
58	Exome-Sequencing Confirms DNAJC5 Mutations as Cause of Adult Neuronal Ceroid-Lipofuscinosis. PLoS ONE, 2011, 6, e26741.	2.5	101
59	Exploration of genetic susceptibility factors for Parkinson's disease in a South American sample. Journal of Genetics, 2010, 89, 229-232.	0.7	37
60	Regulation of ceramide-induced neuronal death: Cell metabolism meets neurodegeneration. Brain Research Reviews, 2009, 59, 333-346.	9.0	92
61	Analysis of functional polymorphisms in three synaptic plasticity-related genes (BDNF, COMT AND) Tj ETQq $1\ 1\ 0$	.784314 r <sub>j</sub> 1.9	gBT /Overloc
62	P4-117 A study of polymorphisms in APOE, ACE, A2M and TAU genes and their relation with lipid and apolipoprotein E serum concentrations in Colombian patients with Alzheimer's disease. Neurobiology of Aging, 2004, 25, S508.	3.1	0